Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.40 |
| ▸ | MAOA | P21397 | 9/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943935 | 0.85 | KDM1A (0.51) | KDM1AMAOAMAOBGAASMN1; SMN2 | |
| SCHEMBL15767640 | 0.85 | KDM1A (0.51) | KDM1AMAOAMAOBGAASMN1; SMN2 | |
| SCHEMBL11700667 | 0.85 | KDM1A (0.51) | KDM1AMAOAMAOBGAASMN1; SMN2 | |
| SCHEMBL7077980 | 0.84 | KDM1A (0.51) | KDM1AMAOAMAOBRCOR1LMNA | |
| SCHEMBL1000359 | 0.84 | KDM1A (0.51) | KDM1AMAOAMAOBRCOR1GAA | |
| SCHEMBL15766917 | 0.84 | KDM1A (0.51) | KDM1AMAOAMAOBRCOR1GAA | |
| SCHEMBL15766918 | 0.84 | KDM1A (0.51) | KDM1AMAOAMAOBRCOR1GAA | |
| SCHEMBL19378682 | 0.82 | CA2 (0.43) | SMN1; SMN2CYP1A2 | |
| SCHEMBL7070199 | 0.81 | KMT2A (0.45) | GAASMN1; SMN2LMNA | |
| SCHEMBL9820967 | 0.81 | KDM1A (0.39) | KDM1AMAOAMAOBRCOR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834013-B2 | Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GLAXOSMITHKLINE LLC | 2009-04-23 | — | — | US | disclosed |
| WO-2005051890-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GPR65, GPR88, GPR84 | KDM1A 3882/4885MAOA 3479/4885MAOB 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.